Spectrum Pharmaceuticals announced that the FDA has approved a “Ready-to-Use” (RTU) formulation of Fusilev (levoleucovorin) for injection. The RTU formulation requires no reconstitution, and is of a higher strength than the currently available lyophilized formulation. Fusilev, the pharmacologically active isomer of leucovorin, is available in vials as freeze-dried powder and single-use vials containing 17.5mL and 25mL sterile solution.
Fusilev rescue is indicated after high-dose methotrexate therapy in osteosarcoma. Fusilev is also indicated to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosage of folic acid antagonists.
For more information call (702) 835-6300 or visit www.sppirx.com.